Intuitive Surgical drops $15m, inks collab dev and licensing deal in Broncus Medical Series A

Broncus Medical said today it raised $15 million in a Series A from robotic surgery giant Intuitive Surgical (NSDQ:ISRG). The investment comes in three parts, including the $15 million equity investment, a technology development collaborative agreement and a licensing deal that will put Broncus Medical’s intellectual properties in Sunnyvale, Calif.-based Intuitive’s hands. Broncus Medical is developing technologies focused on diagnostic and therapeutic lung procedures, and will use funds from the round to support continued development of its lung cancer tech, including clinical trials. The company is currently engaged in a post-market study exploring the performance of Broncus’ tech for total lung navigation procedures and tumor access. “We are delighted to build a relationship with an industry leader like Intuitive, that shares our vision of bringing greater visibility and precision to lung cancer diagnosis and treatment, in order to benefit patients,” Broncus Holding chair Michael Zhao said in a prepared statement. The company touted that it has combined the use of fused fluoroscopy, real-time bronchoscopy and virtual bronchoscopic navigation to provide 3D views within the lungs to improve accuracy and enable more accurate access to nodules for diagnosis and treatment. The post Intuitive Surgical drops $15m, inks collab dev and licensing deal in Broncus Medical Series A appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Imaging Respiratory Broncus Medical Intuitive Surgical Source Type: news

Related Links:

Authors: Mallow C, Hayes M, Semaan R, Smith T, Hales R, Brower R, Yarmus L Abstract INTRODUCTION: Lung cancer is the leading cause of cancer related deaths in the United States. Nearly 85% of all lung cancers are diagnosed at a late stage, with an associated five-year survival rate of 4%. Malignant central airway obstruction and malignant pleural effusions occur in upwards of 30% of these patients. Many of these patients are in need of palliative interventions for symptom control and to help improve their quality of life. Areas covered: This review covers the treatment modalities of malignant central airway obstruc...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
CONCLUSIONS: The data presented here shows that several transcriptomic signatures previously identified as relevant to lung cancer pathogenesis are associated with enrichment of the lower airway microbiota with oral commensals. PMID: 29864375 [PubMed - as supplied by publisher]
Source: American Journal of Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Am J Respir Crit Care Med Source Type: research
CONCLUSIONS:  EBUS-TBNA revealed a specific cause for suspected non-malignant lymphadenopathy in one-third of cases and was associated with excellent specificity. Predominant specific causes were granuloma, besides from tumor. In 3 patients pathogen could be isolated by TBNA. PMID: 29788514 [PubMed - as supplied by publisher]
Source: Pneumologie - Category: Respiratory Medicine Tags: Pneumologie Source Type: research
Authors: Abdelsattar ZM, Blackmon SH Abstract There are many novel technologies that enable complex segmentectomy to be performed. As lung cancer screening becomes more prevalent, patients are increasingly diagnosed with early stage lung cancer, multifocal disease, and second primary tumors. This shift to an earlier clinical presentation combined with advances in technology and an emphasis on minimally invasive techniques have led to the current developments we are now seeing with anatomic segmentectomy. In this paper, we describe the operative technique of an indocyanine green (ICG)-guided video-assisted thoracosc...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Auris Health, previously known as Auris Surgical Robotics, has been named to to CNBC’s Disruptor 50 list, and is the only medical device company to be included. The Redwood City, Calif.-based company was selected due to its focus on lung cancer, which CNBC said kills more individuals in the US than any other type of cancer, and its founder, robotic surgical pioneer and intuitive surgical founder Dr. Frederic Moll. The company has already raised $513 million in equity capital from major tech investors and recently won FDA approval for its robotic Monarch Platform. Topping the list are Elon Musk’s SpaceX, ri...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Robotics aurishealth Source Type: news
Auris Health, previously known as Auris Surgical Robotics, said today it inked a cooperative development and commercialization deal with Johnson &Johnson (NYSE:JNJ) division Ethicon’s NeuWave Medical subsidiary looking to develop systems for the robotically-assisted bronchoscopic ablation of lung lesions. Through the agreement, both companies will help develop an integrated system for robotic control, navigation and application of bronchoscope-delivered microwave ablation. The bronchoscope in development will be equipped with a small camera and accessory channel to allow tools to enter the lungs through the ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Endoscopic / Arthroscopic Respiratory Robotics aurishealth Ethicon johnsonandjohnson NeuWave Medical Inc. Source Type: news
Conclusions: PDT with SuperDimension ENB guidance in the hybrid OR is a novel and feasible approach to control peripheral lung malignancy. PMID: 29732193 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Conclusions: The ENB-guided dye localization by a well-trained thoracic surgeon enables accurate intraoperative identification of GGN or a small pulmonary nodule, with minimal complications and enables minimally invasive surgery including single port surgery. PMID: 29732192 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Rationale: Lung abscess was previously treated surgically, but is now mainly treated with antibiotics and ideally with direct drainage, although postural drainage canalso be used. Patient concerns: A chest abnormal shadow was detected in an 82-year-old man and he was referred to our department in November 2017. On chest computed tomography (CT), a low-density mass shadow was present in the left S8 segment. Lung abscess and lung cancer were considered as differential diagnoses, and treatment with sulbactam sodium/ampicillin sodium (SBT/ABPC) was first initiated for lung abscess. The etiologic agent could not be identif...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Body Vision Medical said today it won FDA clearance for its LungVision lung navigation catheter. The Israel-based company said its LungVision catheter is designed for use in conjunction with standard bronchoscopes and its LungVision system for guiding endotherapy accessories to small pulmonary modules. “Body Vision has pioneered a new generation platform for navigation bronchoscopy that applies augmented reality approach to plan, visualize, and accurately track radiolucent bronchial nodules in real time. LungVision navigation tool has clear performance and cost benefits over current navigation tools that are bound to...
Source: Mass Device - Category: Medical Devices Authors: Tags: Food & Drug Administration (FDA) Imaging Regulatory/Compliance Respiratory Body Vision Medical Source Type: news
More News: Bronchoscopy | Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Respiratory Medicine | Study